Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease.

El-Gohary Y, Fleming A, Zhang H, Estepp JH, Hankins JS, Wang W, Davidoff AM, Murphy AJ.

J Surg Res. 2019 Oct;242:336-341. doi: 10.1016/j.jss.2019.04.077. Epub 2019 May 23.

PMID:
31129243
2.

Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life.

Zahr RS, Rampersaud E, Kang G, Weiss MJ, Wu G, Davis RL, Hankins JS, Estepp JH, Lebensburger J.

Haematologica. 2019 Sep;104(9):e385-e387. doi: 10.3324/haematol.2018.212779. Epub 2019 Mar 19. No abstract available.

3.

Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia.

Claassen D, Boals M, Bowling KM, Cooper GM, Cox J, Hershfield M, Lewis S, Wlodarski M, Weiss MJ, Estepp JH.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003384. doi: 10.1101/mcs.a003384. Print 2018 Dec.

4.

Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.

Zahr RS, Hankins JS, Kang G, Li C, Wang WC, Lebensburger J, Estepp JH.

Am J Hematol. 2019 Jan;94(1):E27-E29. doi: 10.1002/ajh.25329. Epub 2018 Nov 29. No abstract available.

PMID:
30359463
5.

Vaso-occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease.

Mesleh Shayeb A, Smeltzer MP, Kaste SC, Brown A, Estepp JH, Nottage KA.

Pediatr Blood Cancer. 2018 Dec;65(12):e27435. doi: 10.1002/pbc.27435. Epub 2018 Sep 5.

PMID:
30183122
6.

Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.

Hankins JS, Estepp JH, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, Lebensburger JD, Adesina O, Chou ST, Zemel BS, Smeltzer MP, Wang WC, Gurney JG.

Pediatr Blood Cancer. 2018 Sep;65(9):e27228. doi: 10.1002/pbc.27228. Epub 2018 May 24.

PMID:
29797644
7.

Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.

Estepp JH.

Am J Hematol. 2018 Mar;93(3):326-329. doi: 10.1002/ajh.25042. No abstract available.

8.

Safe Use of Low-Molecular-weight Heparin in Pediatric Acute Lymphoblastic Leukemia and Lymphoma Around Lumbar Punctures.

Estepp JH, Smeltzer MP, Kang G, Howard SC, Reiss UM.

J Pediatr Hematol Oncol. 2017 Nov;39(8):596-601. doi: 10.1097/MPH.0000000000000988.

PMID:
28991127
9.

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.

Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS.

Am J Hematol. 2017 Dec;92(12):1333-1339. doi: 10.1002/ajh.24906. Epub 2017 Sep 28.

10.

Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.

Estepp JH, Wiczling P, Moen J, Kang G, Mack JM, Liem R, Panepinto JA, Garg U, Kearns G, Neville KA.

Br J Clin Pharmacol. 2018 Jul;84(7):1478-1485. doi: 10.1111/bcp.13426. Epub 2017 Nov 28.

11.

The clinical severity of hemoglobin S/Black (A γδβ)0 -thalassemia.

Cancio MI, Aygun B, Chui DHK, Rothman JA, Scott JP, Estepp JH, Hankins JS.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26596. Epub 2017 Apr 28.

12.

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J.

Pediatrics. 2016 Jul;138(1). pii: e20153479. doi: 10.1542/peds.2015-3479.

13.

MAGiC: VOC remains but kids with SCA appear.

Estepp JH.

Blood. 2015 Oct 1;126(14):1637-8. doi: 10.1182/blood-2015-08-662502.

14.

Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.

Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee.

J Clin Pharmacol. 2016 Mar;56(3):298-306. doi: 10.1002/jcph.598. Epub 2015 Oct 15.

15.

Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.

Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS.

Pediatr Blood Cancer. 2014 Nov;61(11):2031-6. doi: 10.1002/pbc.25177. Epub 2014 Aug 17.

PMID:
25132074
16.

Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children.

Estepp JH, Smeltzer MP, Wang WC, Hoehn ME, Hankins JS, Aygun B.

Br J Haematol. 2013 May;161(3):402-5. doi: 10.1111/bjh.12238. Epub 2013 Feb 6.

PMID:
23384083
17.

The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children.

Estepp JH, Smeltzer M, Reiss UM.

Pediatr Blood Cancer. 2012 Jul 15;59(1):105-9. doi: 10.1002/pbc.23396. Epub 2011 Nov 21.

PMID:
22106013

Supplemental Content

Loading ...
Support Center